Characterization of sleep habits and medication outcomes for sleep disturbance in children and adults with Angelman syndrome

被引:11
作者
Pereira, Joseph A. [1 ]
Ravichandran, Caitlin T. [1 ,2 ,3 ]
Mullett, Jennifer [2 ]
McDougle, Christopher J. [1 ,2 ,4 ]
Keary, Christopher J. [1 ,2 ,4 ]
机构
[1] Harvard Med Sch, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Lurie Ctr Autism, Lexington, MA USA
[3] McLean Hosp, 115 Mill St, Belmont, MA 02178 USA
[4] Massachusetts Gen Hosp Children, Angelman Syndrome Program, Boston, MA USA
关键词
Angelman syndrome; clonidine; melatonin; sleep disturbance; trazodone; NEURODEVELOPMENTAL DISORDERS; EPILEPSY; QUESTIONNAIRE; ADOLESCENTS; PHENOTYPES; CLONIDINE;
D O I
10.1002/ajmg.a.61642
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The objectives of this study were to characterize the sleep habits of 50 clinically referred individuals with Angelman syndrome (AS) and to retrospectively compare the effectiveness/tolerability of the three most commonly prescribed sleep medications in the sample. An experienced physician assigned a Clinical Global Impressions-Severity scale (CGI-S) score for each subject's AS-specific symptoms. Caregivers completed the Child Sleep Habits Questionnaire (CSHQ; screen for sleep problems in school-aged [4-10 years] children), a screening assessment for sleep problems. Caregivers provided information about medication trials targeting disturbed sleep, with the physician assigning a CGI-Improvement scale (CGI-I) score for each trial. Linear regression showed significant negative association between age and CSHQ score. In their lifetime, 72% of participants had taken a medication for sleep, most commonly melatonin, clonidine and trazodone. The majority continued these for 6 months or longer. With these medications, many demonstrated significant improvement in sleep disturbances, with no difference in odds of improvement between medications. Disturbed sleep was common in this cohort and significantly worse in younger-aged participants. The majority received at least one medication trial for disturbed sleep and each of the most commonly prescribed medication was effective for a substantial percentage of participants. Most participants remained on medication for at least 6 months, suggesting favorable tolerability.
引用
收藏
页码:1913 / 1922
页数:10
相关论文
共 40 条
[1]   Using Bayesian methodology to explore the profile of mental health and well-being in 646 mothers of children with 13 rare genetic syndromes in relation to mothers of children with autism [J].
Adams, Dawn ;
Hastings, Richard P. ;
Alston-Knox, Clair ;
Cianfaglione, Rina ;
Eden, Kate ;
Felce, David ;
Griffith, Gemma ;
Moss, Jo ;
Stinton, Chris ;
Oliver, Chris .
ORPHANET JOURNAL OF RARE DISEASES, 2018, 13
[2]   Evaluation of a behavioral treatment package to reduce sleep problems in children with Angelman Syndrome [J].
Allen, Keith D. ;
Kuhn, Brett R. ;
DeHaai, Kristi A. ;
Wallace, Dustin P. .
RESEARCH IN DEVELOPMENTAL DISABILITIES, 2013, 34 (01) :676-686
[3]  
Bezchlibnyk-Butler K., 2005, CLIN HDB PSYCHOTROPI, V16th
[4]   Angelman syndrome: review of clinical and molecular aspects [J].
Bird, Lynne M. .
APPLICATION OF CLINICAL GENETICS, 2014, 7 :93-104
[5]   Management of Sleep Disorders in Children With Neurodevelopmental Disorders: A Review [J].
Blackmer, Allison Beck ;
Feinstein, James A. .
PHARMACOTHERAPY, 2016, 36 (01) :84-98
[6]   Melatonin for chronic insomnia in Angelman syndrome: A Randomized placebo-controlled trial [J].
Braam, Wiebe ;
Didden, Robert ;
Smits, Marcel G. ;
Curfs, Leopold M. G. .
JOURNAL OF CHILD NEUROLOGY, 2008, 23 (06) :649-654
[7]   Sleep disturbances in Angelman syndrome: a questionnaire study [J].
Bruni, O ;
Ferri, R ;
D'Agostino, G ;
Miano, S ;
Roccella, M ;
Elia, M .
BRAIN & DEVELOPMENT, 2004, 26 (04) :233-240
[8]   Angelman syndrome: evolution of the phenotype in adolescents and adults [J].
Clayton-Smith, J .
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2001, 43 (07) :476-480
[9]   Epilepsy and the sleep-wake patterns found in Angelman syndrome [J].
Conant, Kerry D. ;
Thibert, Ronald L. ;
Thiele, Elizabeth A. .
EPILEPSIA, 2009, 50 (11) :2497-2500
[10]  
DeLorey TM, 1998, J NEUROSCI, V18, P8505